Abstract：The study aims to investigate the situation of drug resistance (DR) to the first and second-line anti-TB drugs, and to provide scientific evidence for clinical treatment and TB control. The absolute concentration method was used in drug susceptibility testing with the first and second-line drugs in 420 clinical isolates from Anhui Province. Among the 420 clinical isolates, the general DR-TB rate and MDR-TB rate were 29.05% and 14.52％, the DR-TB rate and MDR-TB rate for new cases were 15.93% and 6.79％, and the DR-TB rate and MDR-TB rate for retreatment cases were 52.86％ and 30.0%, respectively. The resistance rates for RIF, INH, SM and EMB were 22.14%, 20.0%, 17.38% and 0.95%, respectively. The general second-line drugs (SLD) resistance rate was 22.62%, the drug resistance rates of Levofloxacin (LVFX) and TH were 13.33% (56/420) and 12.86% (54/420) respectively. The drug resistance rate of the acquired patients rose extremely significantly than the initia rate of drug resistance (P<0.05). There was no significant difference between male and female cases. The drug resistance rate of 41-60 age range was the highest among them. It’s indicated that the clinical isolated MTB strains from Anhui Province is very serious in drug resistance. Monitoring of resistance to anti-tuberculosis drugs must be strengthened. It is important that choosing reasonable and efficient anti-TB-drugs based on the result of drug susceptibility test.
徐东芳,王庆,李孳,李东方. 安徽省420株结核分枝杆菌对一线和二线抗结核药物药敏结果分析[J]. 中国人兽共患病学报, 2014, 30(1): 54-57.
XU Dong-fang,WANG Qing,LI Zi,LI Dong-fang. Resistance analysis of the first and second line anti-TB drugs in 420 clinical Mycobacteria tuberculosis isolates from Anhui Province. Chinese Journal of Zoonoses, 2014, 30(1): 54-57.
[1] Word Health Organization. Multidrug and extensively drug-resistant TB(M/XDR-TB): 2010 global report on surveillance and response[R]. Geneva: WHO, 20l0: 5-10. [2]Shah NS, Wright A, Bai GH. Worldwide emergence of extensively drug-resistant tuberculosis[J]. Emerg Infect Dis, 2007, 13(3): 380-387. DOI: 10.3201/eid1303.061400 [3]Basic Professional Committee of Chinese Anti-tuberculosis Association. Tuberculosis diagnosis bacteriology inspection specification[M]. Beijing: China Culture and Education Press, 2006: 56-92. (in Chinese) 中国防痨协会基础专业委员会.结核病诊断实验室检验规程[M].北京:中国教育文化出版社,2006:47-58. [4]World Health Organization. Anti-tuberculosis Drug Resistance in the World: Fourth Global Report: the World Health Organization/International Union against Tuberculosis and Lung Disease (WHO/UNION) Global Project on Anti-Tuberculosis Drug Resistance Surveillance, 2002-2007[R]. Geneva: World Health Organization, 2008. [5]MOH of China. The national TB drug resistance baseline survey report (2007-2008)[R]. Beijing: People’s Health Publishing House, 2010: 3. (in Chinese) 中华人民共和国卫生部. 全国结核病耐药性基线调查报告(2007-2008年)[R].北京:人民卫生出版社2010:3. [6]Helbing P, Altpeter E, Raeber PA, et al. Surveillance of antituberculosis drug resistance in Switzerland 1995-1997: the central link[J]. Eur Respir J, 2000, 16: 200-202. [7]Chinese Medical Association of Respiratory Diseases. Community-acquired pneumonia diagnosis and treatment guidelines[J]. Chin J Tuberrc Respir Dis, 2006, 29: 65l-655. (in Chinese) 中华医学会呼吸病学分会.社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29:65l-655. [8]Wang HY, Wang Y, Yu CB, et al. Study of the status of drug resistant tuberculosis in 12 counties in Shandong[J]. Prev Med Trib, 2008, 14: 1075-106. (in Chinese) 王海英,王燕,于春宝,等.2004-2007年山东省部分结核分枝杆菌耐药情况检测分析[J].预防医学论坛,2008,14:1075-1076. [9]Zhang GL, Du CM, Takuya K, et al. China-Japan cooperation project on second line tuberculosis drug resistance survey in Henan Province[J]. J Med Forum, 2005, 26: 14-16. (in Chinese) 张国龙,杜长梅,苍泽卓也,等.中日合作对河南省结核菌二线药物耐药监测研究[J].医药论坛杂志,2005,26:14-16. [10]Shen X, Li J, Gao Q, et al. A survey on resistance to second-line drugs in patients with pulmonary tuberculosis in Shanghai[J]. Chin J Tuberc Respir Dis, 2011, 34(6): 451-453. (in Chinese) 沈鑫,李静,高谦,等. 2009年上海市耐药肺结核患者二线抗结核药物耐药状况调查[J].中华结核和呼吸杂志,2011,34(6)451-453. [11]Jeon CY, Hwang SH, Min JH, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital[J]. Clin Infect Dis, 2008, 46: 42-49. DOI:10.1086/524017 [12]Toungoussova OS, Mariandyshev AO, Bjune G, et al. Resistance of multidrug resistant strains ofMycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs[J]. Eur J Clin Micmbiol Infect Dis, 2005, 24: 202-206. DOI:10.1007/s10096-005-1284-z
2014, Vol. 30 
